TRML TOURMALINE BIO INC

Tourmaline Bio to Present at the Leerink Partners Global Healthcare Conference 2025

Tourmaline Bio to Present at the Leerink Partners Global Healthcare Conference 2025

NEW YORK, March 03, 2025 (GLOBE NEWSWIRE) -- Tourmaline Bio, Inc. (Tourmaline) (NASDAQ: TRML), a late-stage clinical biotechnology company developing transformative medicines to dramatically improve the lives of patients with life-altering immune and inflammatory diseases, today announced that Sandeep Kulkarni, MD, Co-Founder and Chief Executive Officer, is expected to participate in the following investor conference:

Leerink's Global Healthcare Conference 2025, Miami

Fireside Chat

Tuesday, March 11, 2025, at 4:20 pm ET

A live webcast and replay, when available, will be available under "Events and Presentations" in the News & Investors section of the Tourmaline Bio website at .

About Tourmaline Bio

Tourmaline is a late-stage clinical biotechnology company driven by its mission to develop transformative medicines that dramatically improve the lives of patients with life-altering immune and inflammatory diseases. Tourmaline’s lead asset is pacibekitug (also referred to as TOUR006). For more information about Tourmaline Bio and pacibekitug, please visit or follow us on or .

Media Contact

Scient PR

Sarah Mishek

  

Investor Contact

Meru Advisors

Lee M. Stern



EN
03/03/2025

Underlying

TRMLTOURMALINE BIO INC

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on TOURMALINE BIO INC

Dylan Shindler ... (+2)
  • Dylan Shindler
  • Laura Chico
TRML TOURMALINE BIO INC
05/20/25 May 20, 2025 1 EN
 PRESS RELEASE
Free
TRML TOURMALINE BIO ...

Tourmaline Bio Announces Positive Topline Results from the Ongoing Pha...

Tourmaline Bio Announces Positive Topline Results from the Ongoing Phase 2 TRANQUILITY Trial Evaluating Pacibekitug in Patients with Elevated High-Sensitivity C-reactive Protein and Chronic Kidney Disease – Rapid, deep, and durable reductions in high-sensitivity C-reactive protein (hs-CRP) through Day 90 achieved across all pacibekitug arms with high statistical significance as compared to placebo (p85% hs-CRP reductions from baseline in the 50 mg quarterly arm – – Overall incidence rates of adverse events and serious adverse events in the pacibekitug groups were comparable to placebo thro...

May 20, 2025 1 EN
 PRESS RELEASE
Free
TRML TOURMALINE BIO ...

Tourmaline Bio to Present Topline Results from the Ongoing Phase 2 TRA...

Tourmaline Bio to Present Topline Results from the Ongoing Phase 2 TRANQUILITY Trial of Pacibekitug on May 20, 2025 NEW YORK, May 19, 2025 (GLOBE NEWSWIRE) -- Tourmaline Bio, Inc. (Tourmaline) (NASDAQ: TRML), a late-stage clinical biotechnology company developing transformative medicines to dramatically improve the lives of patients with life-altering immune and inflammatory diseases, will host a conference call and webcast on Tuesday, May 20, 2025 beginning at 8:30 a.m. ET to present topline results from the Phase 2 TRANQUILITY trial evaluating pacibekitug in patients with elevated high-...

May 19, 2025 1 EN
 PRESS RELEASE
Free
TRML TOURMALINE BIO ...

Tourmaline Bio Reports First Quarter 2025 Financial Results and Recent...

Tourmaline Bio Reports First Quarter 2025 Financial Results and Recent Business Highlights – Phase 2 TRANQUILITY trial in patients with elevated high-sensitivity C-reactive protein and chronic kidney disease remains on track for topline data readout in the second quarter 2025 – – Tourmaline expects to provide further details on the clinical development plan for pacibekitug within cardiovascular inflammation in conjunction with reporting TRANQUILITY topline data – – Cash, cash equivalents, and investments of $275.3 million as of March 31, 2025 provide expected cash runway into the ...

May 2, 2025 1 EN
Dylan Shindler ... (+2)
  • Dylan Shindler
  • Laura Chico
TRML TOURMALINE BIO INC
05/02/25 May 2, 2025 1 EN

ResearchPool Subscriptions

Get the most out of your insights

Get in touch